Top Immunodiagnostics Companies

Immunodiagnostics Market size was valued at USD 25.19 Billion in 2024 and is poised to grow from USD 26.25 Billion in 2025 to USD 36.48 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026–2033).

Collaborations and acquisitions are projected to be popular strategies for immunodiagnostics companies looking to expand their business scope going forward. Investing in the development of novel immunodiagnostics products and instruments is also forecasted to create new opportunities for market players in the future. Investing in developing countries is projected to offer lucrative opportunities for immunodiagnostics providers in the long run.   'Abbott (US) ', 'Roche Diagnostics (Switzerland) ', 'DiaSorin (Italy) ', 'Danaher Corporation (US) ', 'QIAGEN (Netherlands) ', 'bioMérieux (France) ', 'Thermo Fisher Scientific (US) ', 'Quest Diagnostics (US)  ', 'Siemens Healthineers AG (Germany) ', 'Bio-Rad Laboratories, Inc. (US) ', 'Sysmex Corporation (Japan) ', 'PerkinElmer, Inc. (US) ', 'Agilent Technologies, Inc. (US) ', 'Mindray Medical International Limited (China) ', 'Grifols, S.A. (Spain) ', 'Becton, Dickinson and Company (BD) (US) ', 'Abcam plc (UK) ', 'Merck KGaA (Germany) ', 'Enzo Biochem, Inc. (US) ', 'Bio-Techne Corporation (US) ', 'Meso Scale Diagnostics, LLC. (US) ', 'GenScript Biotech Corporation (China) ', 'Myriad Genetics, Inc. (US)'

Development of Multiplex Tests: Immunodiagnostics companies can invest in the development of multiplex tests that are capable of detecting several biomarkers to save time and resources. Growing demand for comprehensive diagnostics and screening in clinical settings is also forecasted to make this a prominent immunodiagnostics market trend for companies across the study period and beyond.  

North America is predicted to spearhead the demand for immunodiagnostics in the world. High investments in medical R&D, high healthcare spending potential, and availability of favorable reimbursement policies are expected to be key factors promoting the demand for immunodiagnostics in this region. Moreover, rising adoption of home care and quick adoption of advanced diagnostic technologies are also expected to create new opportunities for immunodiagnostics companies in the long run. The United States and Canada are forecasted to emerge as the most opportune markets in the North American region. The presence of leading immunodiagnostics companies also allows this region to hold sway over the global immunodiagnostics market outlook through 2031.